CHLORTETRACYCLINE/OXYTETRACYCLINE/TETRACYCLINE
83. The Committee agreed to advance (also see para. 73) the proposed draft MRLs in giant prawn and fish to Step 5 (see Appendix V).
CYFLUTHRIN, DANOFLOXACIN AND EPRINOMECTIN
84. The Committee agreed to advance all proposed draft MRLs to Step 5 (see Appendix V). The Committee requested the informal meeting of JECFA and JMPR to consider the harmonization of MRLs and related matters for cyfluthrin (also see paras. 9, 11 and 62-63).
FEBANTEL/FENBENDAZOLE/OXFENDAZOLE
85. The Committee agreed to advance (also see para. 77) the proposed draft MRLs in muscle, liver, kidney and fat of goat and horse to Step 5/8, with a recommendation to omit Steps 6 and 7 (see Appendix III).
FLUAZURON
86. The Committee was informed that since the 48th JECFA five countries had evaluated fluazuron resulting in similar conclusions. The Committee therefore agreed to advance all the proposed draft MRLs to Step 5/8, with a recommendation to omit Steps 6 and 7 (see Appendix III).
FLUMEQUINE
87. The Committee noted that the temporary status of MRLs (except those for cattle) was due to the lack of information on the ratio between marker and total residues, which had been requested for review by JECFA in 2000. It was also noted that 48th JECFA report contained the methodology for deriving ADIs from microbiological endpoints (also see paras. 17-22). The Committee agreed to advance the proposed draft MRLs to Step 5 (see Appendix V).
IMIDOCARB
88. The Committee agreed to advance all the proposed draft MRLs to Step 5 (see Appendix V).
NICARBAZIN
89. The Committee agreed to advance all the proposed draft MRLs to Step 5/8, with a recommendation to omit Steps 6 and 7 (see Appendix III).
PROCAINE BENZYLPENICILLIN
90. The Committee noted that the 50th JECFA had evaluated procaine benzylpenicillin and allocated the ADI and residue definition identical to those of benzylpenicillin as the procaine moiety would not pose toxicological concerns. It was recognized that the proposed MRLs for the tissues of cattle and pig were also at the same levels as those adopted by the Commission for benzylpenicillin. Based on this information, the Committee decided to combine the MRLs for benzylpenicillin and procaine penicillin and to advance them to Step 5/8, with a recommendation to omit Steps 6 and 7 (see Appendices III and VII).
SARAFLOXACIN
91. The Committee agreed to advance (also see paras. 17-22) all the proposed draft MRLs to Step 5 (see Appendix V).
SPECTINOMYCIN
92. The Committee agreed to advance (also see para. 80) the proposed draft MRLs for sheep tissues and chicken eggs to Step 5/8, with a recommendation to omit Steps 6 and 7 (see Appendix III).
